DiaSorin/Luminex: Diagnostics Deal Likely to Draw CFIUS Demands for Mitigation as Chinese JV Stirs Concerns, Security Experts Say

CFIUS and Industrial Security Partner Antonia Tzinova spoke with The Capitol Forum about an Italian diagnostics company's planned buyout of an American medical test maker that is expected to face a detailed U.S. security probe. The Committee on Foreign Investment in the United States (CFIUS) will likely examine whether the diagnostics company is contributing technology and data to a joint venture with the Chinese government, which could increase the risk of unauthorized access to personal data, intellectual property and other research. Ms. Tzinova commented that this situation exemplifies a larger trend of foreign parties attempting to take advantage of a weakened economy to acquire U.S. companies and gain access to data and pioneering research.

"Since the start of the pandemic, CFIUS has been paying particular attention to acquisitions in the biotech industry," she explained.

READ: DiaSorin/Luminex: Diagnostics Deal Likely to Draw CFIUS Demands for Mitigation as Chinese JV Stirs Concerns, Security Experts Say (Subscription required)